Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00106964 · ClinicalTrials.gov registry record · Phase 4
Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth
A Phase 4 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 4
- Development phase
- 371
- Enrollment target
NCT00106964 is a Phase 4 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 371 participants.
The verdict
NCT00106964, a Phase 4 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 371 participants
- Enrollment target
Study Summary
Hepatitis B is a contagious virus that can damage a person's liver. It can be prevented by vaccination, but for many HIV-positive people, the vaccines do not help them achieve adequate protection against this virus. In an attempt to improve response to vaccination and achieve protection from hepatitis B, this trial will compare the immune system response to 3 hepatitis B vaccine regimens in HIV-positive adolescents 12 through 24 years of age.
Interventions
- BIOLOGICAL Engerix-B 20 mcg
- BIOLOGICAL Engerix-B 40 mcg
- BIOLOGICAL Twinrix 720 EIA HAV Ag plus 20 mcg HBsAg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 371 participants |
| Start Date | 2004-01 |
| Est. Completion | 2009-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00106964
The ClinicalTrials.gov registry entry for NCT00106964 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 371 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Engerix-B 20 mcg is the first listed.
NCT00106964 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00106964 about?
NCT00106964 is a clinical study titled "Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth". Hepatitis B is a contagious virus that can damage a person's liver. It can be prevented by vaccination, but for many HIV-positive people, the vaccines do not help them achieve adequate protection against this virus. In an attempt to improve response to vaccination and achieve protection from hepatit...
What is the current status of trial NCT00106964?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 371 participants. The study started on 2004-01. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00106964?
The interventions under investigation include: Engerix-B 20 mcg (BIOLOGICAL), Engerix-B 40 mcg (BIOLOGICAL), Twinrix 720 EIA HAV Ag plus 20 mcg HBsAg (BIOLOGICAL).
Who is sponsoring clinical trial NCT00106964?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.